CITY WHISPERS: Sea lice firm no longer itching to leave London
Daily Mail Benchmark tends to fly under the radar, despite being one of the biggest companies on AIM.
It specialises in the world of aquaculture with its best-known product arguably being medical treatments that kill off sea lice found in farmed salmon.
Last week it bucked a trend that has seen a slew of big firms including building material suppliers CRH and Kingspan quit or threaten to quit the London stock market.
Benchmark is quoted both in the UK and Norway, but had been in talks to ditch AIM in favour of a sole listing in Oslo.
Alongside results last week, the 300 million group revealed that after consulting with shareholders it is staying put.
The City needs all the help it can get with firms such as Okyo Pharma and iEnergizer delisting last week.
So, those on the fence, take note from Benchmark: you can stick around after all.
HOW THIS IS MONEY CAN HELP
- How to choose the best (and cheapest) stocks and shares Isa and the right DIY investing account
'Put up or shut up' offer deadlines loom
Since private equity powerhouse Apollo abandoned takeover bids for Wood Group and THG earlier this month, deal talk in the City now has more than a hint of scepticism.
